Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.
Patients who have agreed to participate in study (written informed consent)
Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.
Patients with patient or guardian consent to participate in study (written informed consent)
Patients who are contraindicated according to national prescribing information
Patients participating in other interventional clinical trials